
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-1Rrp2 CRISPR Activation Plasmid (m) | sc-430727-ACT | 20 µg | $397.00 | |||
IL-1Rrp2 CRISPR Activation Plasmid (m2) | sc-430727-ACT-2 | 20 µg | $397.00 |
Il1rl2 encodes the mouse IL-1Rrp2 receptor, an interleukin-1 receptor family member that contributes to cytokine sensing and downstream inflammatory signaling. Engagement of IL-1 receptor complexes typically interfaces with MyD88-dependent pathways to regulate NF-κB and MAPK transcriptional programs, shaping innate and adaptive immune responses. Expression and signaling through IL-1R family receptors influence leukocyte activation, epithelial barrier responses, and tissue remodeling during inflammation. Dysregulation of IL-1–related signaling networks is frequently studied in models of allergic inflammation, autoimmunity, and infection where altered cytokine responsiveness can modulate disease phenotypes.
IL-1Rrp2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Il1rl2 expression without altering the underlying DNA sequence.
IL-1Rrp2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Il1rl2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Il1rl2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous IL-1Rrp2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Il1rl2 locus and enabling the study of IL-1Rrp2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of IL-1Rrp2 pathway restoration in tumor cells with silenced or reduced Il1rl2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.